EMA: Draft guideline on the clinical investigation of hepatitis-B immunoglobulins

This guideline describes the information to be documented when an application is made for a marketing authorisation for a hepatitis-B immunoglobulin. The guidance covers biological data, pharmacokinetics, clinical trials and patient follow-up. Guidance is also provided for authorised products where a significant change in the manufacturing process has been made.